The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

BACKGROUND: Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornello, Raffaele, Tiseo, Cindy, Frattale, Ilaria, Perrotta, Giulia, Marini, Carmine, Pistoia, Francesca, Sacco, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822439/
https://www.ncbi.nlm.nih.gov/pubmed/31666008
http://dx.doi.org/10.1186/s10194-019-1054-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822439/
https://www.ncbi.nlm.nih.gov/pubmed/31666008
http://dx.doi.org/10.1186/s10194-019-1054-4

Ejemplares similares